AXSM ▲ +0.2% - Axsome Therapeutics, Inc. $AXSM - Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation Axsome Therapeutics rose 0.2% following the company's announcement that it has initiated the SUMMIT Phase 3 trial evaluating AXS-05 as a treatment for smoking cessation. The trial represents a new clinical milestone for the company's investigational therapy and expands its potential market applications. Phase 3 trials are typically viewed positively by investors as they represent advancement toward potential commercialization. 31-AUG-2026 07:00 AM ET